MMIRF (MedMira) Shiller PE Ratio: (As of Sep. 03, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is MedMira Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


MedMira  (OTCPK:MMIRF) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


MedMira Shiller PE Ratio Related Terms


MedMira Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for MedMira's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MedMira Shiller PE Ratio Chart

MedMira Annual Data
Trend Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MedMira Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MMIRF vs VRTX, REGN, MRNA: Shiller PE Ratio Comparison

For the Biotechnology subindustry, MedMira's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedMira Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MedMira's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where MedMira's Shiller PE Ratio falls into.



MedMira Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

MedMira's E10 for the quarter that ended in Apr. 2026 is calculated as:

For example, MedMira's adjusted earnings per share data for the three months ended in Apr. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Apr. 2026 (Change)*Current CPI (Apr. 2026)
=-0.001/132.7364*132.7364
=-0.001

Current CPI (Apr. 2026) = 132.7364.

MedMira Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201607 -0.003 101.844 -0.004
201610 -0.001 102.002 -0.001
201701 -0.001 102.318 -0.001
201704 -0.001 103.029 -0.001
201707 -0.001 103.029 -0.001
201710 -0.001 103.424 -0.001
201801 -0.001 104.056 -0.001
201804 -0.001 105.320 -0.001
201807 -0.001 106.110 -0.001
201810 -0.001 105.952 -0.001
201901 -0.001 105.557 -0.001
201904 -0.001 107.453 -0.001
201907 0.000 108.243 0.000
201910 -0.001 107.927 -0.001
202001 -0.001 108.085 -0.001
202004 -0.001 107.216 -0.001
202007 0.000 108.401 0.000
202010 0.001 108.638 0.001
202101 0.000 109.192 0.000
202104 0.000 110.851 0.000
202107 -0.001 112.431 -0.001
202110 -0.001 113.695 -0.001
202201 -0.001 114.801 -0.001
202204 0.000 118.357 0.000
202207 -0.001 120.964 -0.001
202210 -0.001 121.517 -0.001
202301 -0.001 121.596 -0.001
202304 -0.001 123.571 -0.001
202307 -0.002 124.914 -0.002
202310 -0.001 125.310 -0.001
202401 -0.001 125.072 -0.001
202404 -0.001 126.890 -0.001
202407 -0.001 128.075 -0.001
202410 -0.001 127.838 -0.001
202501 -0.001 127.443 -0.001
202504 -0.001 129.102 -0.001
202507 -0.001 130.290 -0.001
202510 -0.001 130.603 -0.001
202601 -0.001 130.366 -0.001
202604 -0.001 132.736 -0.001

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


MedMira Business Description

Other Exchanges MIR:Canada
Address 155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3
MedMira Inc is a biotechnology company engaged in the research, development, and manufacturing of rapid diagnostics and technologies. The company operates in one reportable operating segment, rapid diagnostic products and services. Its product line includes HIV, COVID-19, syphilis, Multiplex, Miriad RVF Toolkit, and H. pylori. The company generates revenue from North America, Europe, and other regions, with the majority generated from North America.